Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15097770 | 0.96 | PPARD (0.74) | PPARDPPARA | |
| SCHEMBL15097825 | 0.96 | PPARD (0.66) | PPARDPPARA | |
| SCHEMBL11926062 | 0.94 | PPARD (0.73) | PPARDPPARA | |
| SCHEMBL11926059 | 0.94 | PPARD (0.73) | PPARDPPARA | |
| SCHEMBL15097727 | 0.94 | PPARD (0.66) | PPARDPPARA | |
| SCHEMBL15097201 | 0.94 | PPARD (0.65) | PPARDPPARA | |
| SCHEMBL15097812 | 0.92 | PPARD (0.60) | PPARDPPARA | |
| SCHEMBL15097847 | 0.91 | PPARD (0.64) | PPARDPPARA | |
| SCHEMBL15142611 | 0.90 | PPARD (0.61) | PPARDPPARA | |
| SCHEMBL15142374 | 0.89 | PPARD (0.55) | PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130197043-A1 | USE OF THE FETAL REPROGRAMMING OF A PPAR AGONIST | SNU R&DB FOUNDATION (KR) | 2013-08-01 | — | — | US | disclosed |
| EP-2612669-A2 | USE OF THE FETAL REPROGRAMMING OF A PPAR AGONIST | SNU R & DB Foundation (KR) | 2013-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197043-A1 | USE OF THE FETAL REPROGRAMMING OF A PPAR AGONIST | PPARD, PPARA, PPARG | PPARD 1/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.